BRIEF—Idorsia and Syneos expand commercialization deal

Swiss biotech Idorsia and Syneos Health have extended an existing collaboration to commercialize daridorexant for the treatment of insomnia across Europe and Canada.

The novel dual orexin receptor antagonist was recently approved in this indication in the USA, where it will be marketed as Quviviq. A submission for European approval was made in March 2021.

Chief commercial officer Simon Jose said: “Daridorexant represents a significant advance in the treatment of insomnia, and it is now our job to transform and modernize insomnia treatment, notably in Europe where it would be the first dual orexin receptor antagonist available to patients.”

He added: “While we are building the core capabilities needed for a successful launch ourselves, the extension of our existing relationship with Syneos Health will allow us to create a best-in-class sales organization to effectively reach the primary care market in Europe and Canada.”